glp-1 cardiovascular outcomes trial results august 2025 Kidney and Among Patients With CKD Receiving Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials A network meta-analysis backed weight-loss

The dosing landscape right now No standardized microdosing protocol exists yet

Similarly, GLP-1RA have shown to have a neuroprotective effect including delay in Alzheimers and Parkinsons disease onset as well progressions (118)

Prevent Muscle Wasting with Weight Training One of the concerns about any metabolic support program is a higher percentage loss of lean body weight or muscle mass than metabolic changes achieved through diet and lifestyle changes

That flexibility may improve convenience and long-term adherence for some patients

Handling the half-unit challenge Most standard insulin syringes do not have half-unit markings

Some people lose significant thigh fat during GLP-1 treatment, particularly those on higher doses of tirzepatide or retatrutide , which can reduce the suitability of this site over time